Demonstrates improved risk stratification in hepatitis patients with cirrhosis, suggesting better management outcomes.
Severe immune checkpoint inhibitor–associated hepatitis may progress despite only modest aminotransferase elevations, particularly in patients with cirrhosis. Recognition of atypical presentations and integration of clinical, radiologic, and multidisciplinary assessment may improve risk stratification and guide timely management of clinically significant hepatic injury.
No takes yet. Share an insight, caveat, or question.
Elendu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: